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Abstract 
Phosphoinositide 3-kinase (PI3K) plays an important role in platelet function and contributes 
to platelet hyperreactivity induced by elevated levels of circulating peptide hormones, 
including thrombopoietin (TPO). Previous work established an important role for the PI3K 
isoform; p110β in platelet function, however the role of p110α is still largely unexplored. Here 
we sought to investigate the role of p110α in TPO-mediated hyperactivity by using a 
conditional p110α knockout (KO) murine model in conjunction with platelet functional assays. 
We found that TPO-mediated enhancement of collagen-related peptide (CRP-XL)-induced 
platelet aggregation and adenosine triphosphate (ATP) secretion were significantly increased 
in p110α KO platelets. Furthermore, TPO-mediated enhancement of thrombus formation by 
p110α KO platelets was elevated over wild-type (WT) platelets, suggesting that p110α 
negatively regulates TPO-mediated priming of platelet function.  The enhancements were not 
due to increased flow through the PI3K pathway as phosphatidylinositol 3,4,5-trisphosphate 
(PI(3,4,5)P3) formation and phosphorylation of Akt and glycogen synthase kinase 3 (GSK3) 
were comparable between WT and p110α KO platelets. In contrast, extracellular responsive 
kinase (ERK) phosphorylation and thromboxane (TxA2) formation were significantly enhanced 
in p110α KO platelets, both of which were blocked by the MEK inhibitor PD184352, whereas 
the p38 MAPK inhibitor VX-702 and p110 inhibitor PIK-75 had no effect. Acetylsalicylic acid 
(ASA) blocked the enhancement of thrombus formation by TPO in both WT and p110α KO 
mice.  Together, these results demonstrate that p110α negatively regulates TPO-mediated 
enhancement of platelet function by restricting ERK phosphorylation and TxA2 synthesis in a 
manner independent of its kinase activity.  
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1.Introduction 
The production of the second messenger molecule PtdIns(3,4,5)P3 (PIP3) in response to 
agonist stimulation is well established in playing a vital role supporting platelet activation and 
thrombus formation. This second messenger molecule is the product of the class I 
phosphoinositide 3-kinases (PI3K) phosphorylation of phosphatidylinositol (4,5)-
bisphosphate (PIP2). All four catalytic isoforms of PI3K (p110α, p110β, p110δ, and p110γ) are 
expressed in platelets with evidence using pharmacological agents and genetic models 
determining that the p110β isoform plays a dominant role in regulating platelet function[1-5] 
, whereas the other isoforms (p110α, p110δ, and p110γ) are thought to play important 
ancillary roles in promoting platelet activation[6-10].  
 
Initial work examining the role of the p110α isoform using the isoform selective inhibitor PIK-
75 suggested that it was involved in supporting GPVI-induced platelet activation[1, 11] and 
thrombus formation. However, these findings could be attributed to PIK-75’s inhibitory action 
on multiple PI3K isoforms at higher concentrations[6, 12, 13]. Use of genetic models and 
appropriate pharmacological inhibition has in fact determined that loss/inhibition of p110α 
does not dampen platelet activation in response to platelet agonists or result in reductions in 
thrombus formation[5, 6, 14].  
 
However, p110α does appear to play a role in regulating the ability of primers, which do not 
induce platelet aggregation by themselves, but potentiate platelet activation induced by low 
agonist doses and can increase platelet adhesion and thrombus growth on collagen. The 
priming abilities of both IGF-1 and antiphospholipid antibodies were found to be altered using 
isoform selective inhibitors and mice with megakaryocyte/platelet lineage-specific 
inactivation of p110α, with p110 also playing a supporting role[6, 14].  
 
Here, we extended these studies to the haematopoietic cytokine thrombopoietin (TPO). The 
primary physiological function of this cytokine is to regulate megakaryocyte (MK) 
differentiation/maturation and platelet production by binding to the cellular homologue of 
the myeloproliferative leukaemia virus oncogene (c-Mpl) receptor[15]. Platelets also express 
c-Mpl and binding of TPO enhances platelet activation by platelet agonists via JAK2 and 
PI3K[16] and increasing TxA2 production via ERK1/2[17, 18] . We hypothesised that deletion 
of p110α would result in a reduction in the ability of TPO ability to enhance platelet activation 
and thrombus formation. However, in contrast we demonstrate that deletion of p110α results 
in significant enhancements of GPVI-mediated platelet activation and thrombus formation in 
the presence TPO. This is the first study to demonstrate a negative role for the PI3K isoform 
p110α in regulating platelet function and thrombosis. 
 
  
2. Materials and Methods 
 
2.1 Materials 
Cross-linked collagen-related peptide (CRP-XL) was from R. Farndale (Department of 
Biochemistry, University of Cambridge, UK).  Fibrillar HORM collagen (type I) derived from 
equine tendon from Takeda (Linz, Austria). Recombinant murine thrombopoietin (TPO) was 
from PeproTech (London, UK). D-phenylalanyl-L-propyl-L-arginine chloromethyl ketone 
(PPACK) was from Calbiochem (Merck Chemicals, Watford, UK). 3,3'-Dihexyloxacarbocyanine 
iodide (DiOC6) and TxB2 ELISA kit were from Enzo Life Sciences (Exeter, UK). CHRONO-LUME® 
reagent was from CHRONO-LOG (Labmedics, Abingdon, UK). AktS473 (#4060), AktT308 (#13038), 
Akt (#9272), ERK1/2T202/Y204 (#9101), GSK-3α/βS21/9 (#9331), JAK2Y1007/1008 (#3771), JAK2 
(#3230), p110α (#4249), Phospho-(Ser) PKC Substrate (#2261), STAT5/Y694 (#4322), and 
STAT5/ (#9358) were from Cell Signaling Technology (New England Biolabs, Hitchin, UK). 
GAPDH (#sc-25778) antibody was from Santa Cruz Biotechnology (Insight Biotechnology, 
Middlesex, UK). PD184352, VX-702 and TGX-221 were from Bio-Techne (Abingdon, UK).  PIK-
75 and A66 were from Cayman Chemicals (Cambridge Bioscience, Cambridge, UK). Secondary 
antibodies for immunoblotting were from Jackson Immunoresearch (Stratech Scientific, Ely, 
UK). All other reagents were from Sigma (Poole, UK), unless otherwise indicated. 
 
2.2 Mice 
All animal studies were approved by the local research ethics committee at the University of 
Bristol, UK and mice were bred and maintained for this purpose under the United Kingdom 
Home Office project license PPL30/3445. p110 flox/flox:Pf4-Cre mice are as previously 
described[6]. p110αflox/flox:Pf4-Cre- mice are henceforth referred to as wild-type (WT) and 
p110α flox/flox:Pf4-Cre+ mice as knockout (KO).  
 
2.3 Murine platelet preparation 
Age and sex-matched mice, 8-24 weeks of age were sacrificed by rising CO2 inhalation, in 
accordance with Schedule 1 of the Animals (Scientific Procedures) Act (ASPA), 1986. Blood 
was drawn from the inferior vena cava into a syringe containing 4% trisodium citrate (1:10 
v/v). Washed platelets were then prepared as previously described[6, 19].   
 
2.4 Platelet aggregation 
Platelet aggregation was monitored as previously described[20]. Briefly, washed platelets 
(2×108/mL) were stimulated with agonist and aggregation monitored using a CHRONO-LOG 
490-4D aggregometer at 37°C under stirring conditions.  
 
2.5 ATP secretion 
ATP secretion as a measure of platelet δ-granule secretion was monitored in a 96-well plate 
using the luciferin-luciferase reagent; CHRONO-LUME® [52-54]. Luminescence was monitored 
using a Tecan Infinite M200 PRO plate reader (Tecan Group Ltd, Switzerland). ATP standard 
(0.8 nM) was employed to calibrate the readings and results are expressed as area under the 
curve. 
 
2.6 In vitro thrombus formation 
In vitro thrombus formation assays were performed under non-coagulating conditions, as 
previously described[6, 21, 22]. Briefly, anticoagulated blood labelled with DiOC6 (10 min) was 
perfused at 1000 s-1 for 2 min over either collagen-coated (50 µg/mL) Ibidi µ-Slide VI 0.1 
(Thistle Scientific Ltd, UK) flow-chambers or Vena8 glass-bottomed biochips (Cellix Ltd 
Microfluidic Solutions, Ireland). Vena8 glass-bottomed biochips (Cellix Ltd Microfluidic 
Solutions, Ireland) were used for analysing the effect of ASA on thrombus formation to 
improve resolution of platelet deposition as a monolayer. Platelets were fixed by perfusing 
4% paraformaldehyde solution across each of the test channels for 2 min. Non-adherent cells 
and excess fixative were removed by flushing channels. Data was imaged using a Leica SP5-II 
confocal laser scanning microscope attached to a Leica DMI 6000 inverted epifluorescence 
microscope (Leica Microsystems, UK). Confocal z-stacks (512 x 512 pixels, stack distance 1 
µm) from five randomly chosen fields of view per channel were captured with a 40X oil-
immersion objective. Quantification of surface coverage was performed with Image J 1.46 
(NIH, USA) and Volocity 6.1.1 quantitation software (Perkin Elmer Inc, USA). 
 
2.7 Platelet phosphoinositide measurement by lipidomic mass spectrometry  
PtdIns(3,4,5)P3 generation was measured as previously described[23]. Briefly washed 
platelets were treated as indicated and reactions terminated by the addition of ice-cold 1 M 
hydrochloric acid. Platelets were pelleted (12, 000 xg, 10 min, 4oC) and snap-frozen. Mass 
spectrometry was used to measure inositol lipid levels essentially as previously described 
[24], using a QTRAP 4000 mass spectrometer (SCIEX, AB Sciex UK Ltd, Warrington, UK) and 
employing the lipid extraction and derivatization method described for cells in suspension, 
with the modification that 10 ng C17:0/C16:0 PtdIns(3,4,5)P3 internal standard (ISD) and 100 
ng C17:0/C16:0 PtdIns ISD were added to primary extracts, and that final samples were dried 
in a speed-vac concentrator rather than under N2. 
 
2.8 Protein extraction and immunoblotting: 
Washed platelets (4x108/mL) were treated as indicated and lysed directly in 4X NuPAGE 
sample buffer containing 0.5 M DTT. Lysates were analysed by SDS-PAGE/western-blotting 
using 7% (w/v) bis-tris gels as previously described[25]. Proteins were visualised by ECL or 
near-infrared detection using a LI-COR® Odyssey imaging system. Densitometry was 
conducted using Image J or LI-COR® Image Studio.  
 
2.9 Measurement of TxA2 production 
To assess TxA2 levels, the stable metabolite TxB2 was analysed using a commercial ELISA kit 
(Enzo Life Sciences, Exeter, UK) as previously described [21]. Briefly, platelets (4×108/mL) in 
the absence of indomethacin were stimulated under non-stirring conditions (37oC) before 
addition of EDTA (5 mM) and indomethacin (200 μM).  Platelets were pelleted (4 min, 12,000 
×g) and supernatant collected. TxB2 levels were assessed according to manufacturer's 
protocol. 
 
2.10 Data Analysis 
Data were analysed using GraphPad Prism 7 software. All data are presented as the mean ± 
s.e.m of at least three independent observations. Data presented with statistical analysis 
were tested using one-way/two-way ANOVA as appropriate with Sidak’s multiple comparison 
post-hoc test. 
 
3. Results 
 
3.1 Deletion of p110α results in amplification of TPO’s ability to enhance GPVI-induced 
platelet activation and thrombus formation.   
TPO is unable to induce platelet functional responses (aggregation, granule secretion and 
thrombus formation) by itself, but is known to potentiate GPVI-mediated platelet function, δ-
granule secretion and Ca2+ mobilization via a PI3K-dependent mechanism[26-28]. In line with 
these findings, we found that TPO alone did not evoke platelet aggregation or ATP secretion. 
However, TPO did enhanced platelet aggregation induced by a sub-threshold concentration 
(0.2 g/mL) of CRP-XL (Fig.1Ai), as well as ATP release elicited by a range of CRP-XL 
concentrations (Fig.1B).  Platelet responses to CRP-XL or TPO were unaltered in platelets 
where p110α was knocked-out, this agrees with our previous findings[6]. In contrast, p110α 
KO platelets exhibited increased responsiveness to the combined CRP-XL and TPO 
stimulation. This was illustrated by an increase in maximum aggregation from ~10% in the WT 
samples to ~70% in KO platelets (Fig. 1A), and a significant increase in the area under the 
aggregation curve (Fig. 1Aii). ATP secretion in response to co-stimulation was also enhanced 
(Fig.1B). TPO was also able to enhance protease-activated receptor (PAR)-mediated platelet 
functional responses in both WT and KO platelets, however we did not observe any 
enhancement in responsiveness to combined PAR-peptide (AYPGKF) and TPO stimulation in 
KO platelets (data not shown). When we examined thrombus formation on collagen at arterial 
shear-rates (1000 s-1), we found that deletion of p110α from platelets did not alter thrombus 
formation on collagen (Fig. 2A, B), which is in agreement with previous studies[5, 6, 14]. Pre-
treatment of whole blood with TPO (100 ng/mL) enhanced platelet deposition on collagen in 
both WT and KO samples (Fig.2Ai,ii). However, the amount of platelet deposition induced by 
TPO was greater in the KO samples compared to WT (Fig.2Ai,ii). We found that despite the 
area covered by thrombi (%) (Fig.2A, B) at the thrombus base (0 µm) being comparable 
between WT and KO samples (Fig.2A, B), there was an increase in area covered at the +4, +8 
and +12 µm z-planes in KO samples, which correlated with a significant increase in total 
thrombus volume (Fig.2C). This increase cannot be accounted for by alterations in 
haematological parameters as platelet counts and mean-platelet volume were comparable 
between WT and KO samples (data not shown, [6]). Together these data indicate that p110α 
negatively regulates the ability of TPO to enhance GPVI-induced platelet activation. 
 
3.2 Signalling directly downstream of c-MPL is unaltered in p110 KO platelets.  
One potential explanation for the enhancement in TPO-mediated increases in platelet 
aggregation, secretion and thrombus formation in p110 KO platelets is that signalling 
directly downstream of the TPO receptor; c-MPL is enhanced. c-MPL doesn’t possess intrinsic 
tyrosine kinase activity itself and instead relies on transactivation of associated JAK2. The 
active/phosphorylated JAK2 will subsequently phosphorylate tyrosine residues on the 
receptor leading to the recruitment and phosphorylation of SH2 domain containing proteins 
such as STAT5/.  As expected stimulation of platelets with TPO but not CRP-XL induced 
tyrosine phosphorylation of JAK2 at Tyr1007/1008 and STAT5/ at Tyr694 (Fig.3A). 
Combined treatment of platelets with CRP-XL and TPO did not induce any further increases in 
either JAK2 Tyr1007/1008 or STAT5/ Tyr694 phosphorylation. The deletion of p110 did 
not significantly alter phosphorylation of JAK2 or STAT5/ compared to WT platelets 
(Fig.3Ai-iii). Together, these results demonstrate that enhancements in TPO priming of 
platelet function are not due to increased signalling through c-MPL/JAK2.  
 
3.3 Enhancement of TPO-mediated priming is not due to increased flow through the PI3K 
pathway.  
To further explore the enhancement in TPO-mediated priming observed in p110α KO platelets 
we examined whether there was an up-regulation in PI3K signalling. The p110α isoform 
belongs to the class I PI3K family of kinases which predominantly regulates cell function by  
preferentially phosphorylating PI(4,5)P2 to the second messenger PI(3,4,5)P3[29]. Platelets 
have an extensive PI(3,4,5)P3 interactome comprising a vast array of PI3K effectors known to 
play important roles  in platelet activation[23]. Consequently, the effect of TPO administration 
on GPVI-induced PI(3,4,5)P3 formation was explored. CRP-XL, TPO and a combined treatment 
of CRP-XL and TPO were all observed to increase PI(3,4,5)P3 levels in platelets (Fig.3B). The 
amount of PI(3,4,5)P3 formation induced by these treatments was however not significantly 
altered in p110 deficient platelets (Fig.3B). In agreement with these findings, 
phosphorylation of the major PI3K effector Akt at Thr308 and of the Akt substrate GSK3 at 
Ser21/9 in response to CRP-XL, TPO or CRP-XL+TPO were unaltered in KO platelets compared 
to WT platelets (Fig.3Ci, ii, iv). Interestingly, phosphorylation of Akt at Ser473 induced by CRP-
XL alone was significantly elevated in p110α KO platelets (Fig.3Ciii), supporting previous 
studies that suggest that the more reliable marker of Akt activity is phosphorylation of the 
Thr308 site[30]. Taken together, these results demonstrate that enhanced TPO-mediated 
priming of GPVI platelet activation in p110α-deficient platelets is not due to increased flow 
through the PI3K pathway. 
 
3.4 Blockade of TxA2 production ablates the enhancement in TPO-mediated priming in WT 
and p110α KO platelets. 
TxA2 is known to play an important role in the amplification of platelet responses to 
physiological stimuli and has been reported to contribute to TPO-mediated enhancement of 
platelet function [17, 18, 31]. Considering this, we were interested to investigate whether 
enhanced TxA2 production may underlie the p110α KO hyperreactive platelet phenotype. 
Indeed, we found that pre-treatment of p110α KO platelets with TPO (100 ng/mL) resulted in 
a significantly greater increase in TxA2 generation than in WT platelets (Fig. 4A). Increases in 
TxA2 generation induced by TPO were concentration-dependent (3 – 100 ng/mL) with a trend 
for enhancement in TxA2 in the KO platelets occurring across the concentration range 
(S.Fig1A). To test whether the elevation in TxA2 production was driving the hyperreactive 
phenotype of p110α KO platelets, whole blood samples were pre-treated with the COX 
inhibitor, ASA and platelet deposition on collagen under the influence of TPO treatment was 
monitored. Interestingly, ASA not only ablated the elevation in TPO-mediated priming of 
thrombus formation in p110α KO samples, but also blocked TPO’s priming effect on WT 
platelets (Fig. 4B, C). Taken together, these findings suggest that (i) TxA2 production plays a 
critical role in TPO-mediated priming of platelet function and thrombus formation and that 
(ii) enhanced TxA2 production is a critical driver of the hyperreactive phenotype observed in 
p110α KO platelets. 
 
3.5 Increased TxA2 production is blocked by MEK1/2 inhibition and correlates with 
increased activation of ERK.  
We were interested to explore the underlying mechanism by which p110 deletion could 
regulate an enhancement in TxA2 production. Agonist-induced p38 MAPK/ERK signalling has 
been implicated in the activation of cytosolic phospholipase A2 (cPLA2), an enzyme that drives 
arachidonic acid (AA) production and subsequently triggers the formation of TxA2 in 
platelets[18, 32-34]. Here we show that pre-treatment of platelets with the MEK1/2 inhibitor 
PD184352 resulted in a significant reduction in TxA2 generation elicited by CRP-XL and TPO 
(Fig.5A). Furthermore, in the presence of PD184352 the level of TxA2 generation in p110α KO 
samples was comparable to WT. In contrast, optimal concentrations of the p38 inhibitor VX-
702 and the p110α inhibitor PIK-75 did not alter TxA2 generation (Fig.5A), whereas the p110 
inhibitor TGX-221 blocked responses under all conditions. The findings with PIK-75 suggest 
that the p110α KO platelet phenotype is not due to an absence of p110α kinase activity; 
similar findings were observed with the p110 inhibitor A66 (S.Fig1B). The results with 
PD184352 and VX-702 highlight that ERK but not p38 plays an important role in regulating the 
enhancement in TxA2 synthesis observed in p110 KO platelets. In support of these findings, 
we found that phosphorylation of ERK1/2 at Thr202/Tyr204 was significantly enhanced in 
p110α KO platelets (Fig.5Bi, ii), whereas the phosphorylation of p38 at Thr180/Tyr182 and of 
the PKC substrate pleckstrin were unaltered (Fig.5Bi, iii, iv). Together, these results 
demonstrate an important role for ERK in TPO-mediated enhanced TxA2 synthesis in p110α 
KO platelets in a manner that is independent of the loss of p110α kinase activity.  
 
4. Discussion 
TPO is unable to independently induce platelet aggregation and granule secretion, but in 
combination with an array of physiological stimuli can enhance platelet functional 
responses[16, 26, 31, 35, 36]. Platelets play a pivotal role in thrombosis, a process that 
contributes to the pathogenesis of cardiovascular disease[37, 38]. Elevated levels of TPO 
brought about by various clinical conditions or chronic cigarette smoking may contribute to 
platelet hyperreactivity and consequently cardiovascular disease[39-45]. PI3K p110α has 
previously been shown to be involved in primer-mediated enhancement of platelet function, 
therefore we explored the contribution of p110α to TPO-mediated enhancement of platelet 
function.  Surprisingly, we found that p110α negatively regulates TPO’s ability to enhance 
GPVI-induced platelet activation and thrombus formation, in a process dependent on 
alterations in ERK signalling and TxA2 production.  
 
This is the first study to demonstrate that exogenous addition of TPO can potentiate platelet 
deposition and thrombus formation on a collagen-coated surface under conditions of arterial 
shear (1000s-1). TPO treatment not only significantly increased the collagen area covered with 
platelets, but also significantly enhanced the total thrombus volume compared to vehicle-
treated platelets. In contrast, van Os and colleagues[46] found that TPO did not enhance 
platelet thrombus formation on collagen type III under conditions of shear. The difference 
may be explained by the use of collagen type I in our study, which comprises of large fibres 
that have higher thrombogenic activity and induce more potent activation of GPVI in platelets 
than collagen type III[47, 48].  
 
In this study, we observed that genetic deletion of p110α from platelets heightened the ability 
of TPO to enhance CRP-XL-mediated platelet aggregation and thrombus formation on 
collagen. This suggests a role for p110α as a negative regulator of TPO-induced increases of 
GPVI-mediated platelet function. This enhancement was not due to upregulation of other 
PI3K isoforms as genetic deletion of p110α does not cause alterations in the expression levels 
of other class I PI3K isoforms in this specific p110α murine model[6]. Although this is the first 
time that PI3K p110α has been demonstrated to negatively regulate platelet function, similar 
negative regulatory roles of p110α have previously been reported in BON (human endocrine 
cell line) cells, whereby the isoform negatively regulates secretion; while, in cardiomyocytes 
p110α negatively controls GPCR (G protein-coupled receptor)-induced ERK and Akt 
activation[49, 50]. In platelets however, p110α’s capability to negatively regulate TPO’s 
priming effect on platelet function is likely to occur via a PI(3,4,5)P3-independent mechanism, 
as PI(3,4,5)P3 generation in WT and KO samples was comparable. Additionally, TPO did not 
significantly enhance GPVI-induced phosphorylation of the PI3K effector; Akt at Thr308 or 
Akt’s substrate; GSK3, in p110α KO platelets. Consequently, the amplification of TPO-
mediated enhancements may be due to negative regulation of a pathway downstream of 
and/or parallel to PI3K. Alternatively, it may suggest that p110α acts as a negative regulator 
via a kinase-independent mechanism. Indeed, we found that the platelet p110α phenotype 
could not be mimicked by the presence of the p110α inhibitor PIK-75. Kinase-independent 
functions of p110α have recently been described in cells with gain-of-function mutations in 
the p110α gene (PIK3CA; hot spot mutations in E545K/H1047R)[51]. Lipid kinase-independent 
functions have also been demonstrated for the Class I PI3K isoforms p110β and p110δ, which 
contribute to insulin signalling and cell survival respectively[52, 53]. Considering the other 
reported lipid kinase-independent functions of the Class I PI3K isoforms in other cells, it is 
plausible that p110α can negatively regulate TPO-mediated enhancement of platelet function 
via a similar mechanism.  
 
TPO’s priming effect on GPVI-mediated ATP release (δ-granule secretion), ERK 
phosphorylation and TxA2 production were also elevated in p110α KO platelets. Pasquet and 
colleagues have previously demonstrated that TPO can enhance GPVI-induced Ca2+ 
mobilization[26], which in turn results in PKC activation and subsequent ERK activation[54]. 
ERK has been shown to regulate cPLA2 and subsequently TxA2 generation in platelets[18]. 
Interestingly, we found that the COX inhibitor, ASA, which inhibits TxA2 synthesis, not only (i) 
ablated the elevated TPO-mediated enhancement of thrombus formation on collagen 
demonstrated by p110α KO platelets but (ii) blocked TPO-induced enhancements in WT 
samples also. Enhanced TPO-mediated increases in ATP secretion in the p110α KO platelets 
did not appear to compensate for the loss of TxA2 production following ASA treatment. 
Indeed, TPO-mediated potentiation of GPVI-induced platelet aggregation can occur in the 
presence of the ADP scavenger, apyrase, suggesting that TPO-induced functional 
enhancement is at least partially ADP-independent[26]. Studies have also demonstrated that 
ASA inhibits TPO-mediated enhancement of ADP-induced secondary aggregation, possibly 
explaining the inability of ADP to compensate for the loss of TxA2 production in whole blood 
samples treated with ASA[17]. Taken together these data demonstrate that TPO-mediated 
enhancement of GPVI-induced platelet function is driven by TxA2 generation and this process 
is negatively regulated by PI3K p110α.  
 
In conclusion, we have demonstrated (i) the ability of TPO to enhance thrombus formation 
on collagen and (ii) that the PI3K isoform p110α negatively regulates TPO-mediated 
enhancement of TxA2 generation and consequently platelet function. This is the first study to 
show a kinase- independent negative regulatory role for PI3K p110α in platelet function. 
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Figure Legends 
 
Figure 1. Deletion of p110 enhances TPO-mediated priming of CRP-XL-induced platelet 
aggregation and -granule secretion.  A) Representative aggregation traces (i) and area under 
the curve analysis of platelet aggregation (ii) induced by sub-maximal CRP-XL (0.2 g/mL) in 
WT and KO platelets (2x108/mL) in the absence or presence of TPO (100 ng/mL, 5 min). 
Aggregation was monitored (5 min, 37oC) under continuous stirring conditions (1200 rpm) 
using a CHRONO-LOG 490-4D aggregometer. Data demonstrates that deletion of p110 from 
platelets results in a significant enhancement in TPO-mediated priming of CRP-XL-induced 
platelet aggregation. n =3 ± s.e.mean. B) Analysis of ATP release as a measure of -granule 
secretion from WT and KO platelets stimulated with CRP-XL in the absence or presence of 
TPO (100 ng/mL, 5 min). ATP release was monitored using CHRONO-LUME® reagent on a 
Tecan Infinite M200 PRO plate reader. Data are expressed as area under the curve (AU), n = 
4 ± s.e.mean. Statistical analysis was performed using a two-way ANOVA followed by Sidak’s 
multiple comparison post-hoc test. **; p < 0.01. 
 
Figure 2. Deletion of p110 results in amplification of TPO-mediated priming of thrombus 
formation on collagen. A) Representative images of platelet deposition on collagen acquired 
from the collagen base (z-position = 0 µm) at 4 µm increments to a max thrombus height of 
12 µm as indicated. Fluorescently labelled anti-coagulated whole blood from WT (i) and 
p110α KO mice (ii), pre-treated with either vehicle (HEPES-Tyrode’s) or TPO (100 ng/mL, 5 
min) was perfused at an arterial shear rate of 1000s-1 over collagen-coated (50 µg/mL, 2 min) 
Ibidi µ-Slide VI 0.1 (Thistle Scientific Ltd, UK) flow-chambers, before fixation with 4% PFA.  
Images were acquired using a Leica SP5-II confocal LSM.  B) Analysis of area coverage and C) 
total thrombus volume performed using Image J 1.46 (NIH, USA) and Volocity 6.1.1 (Perkin 
Elmer Inc, USA) revealed that deletion of p110 results in an amplification of TPO’s ability to 
enhance the area covered by platelets (%) across the various z-positions and the total 
thrombus volume (µm3). Data represent the average results taken from 5 random microscopic 
fields per experimental condition, n = 7 ± s.e.mean. Statistical analysis was performed using 
a two-way ANOVA followed by Sidak’s multiple comparison post-hoc test. *; p < 0.05, **; p < 
0.01, ***; p < 0.001.   
 
Figure 3. Deletion of p110α does not increase flow through the PI3K pathway. A) 
Representative immunoblot examining the activation of JAK2/STAT5 induced by CRP-XL (1 
g/mL), TPO (100 ng/mL) and CRP-XL+TPO. Histograms demonstrate phosphorylation of JAK2 
at Tyr1007/1008 and STAT5/ at Tyr694 are comparable between WT and KO platelets, n = 
4 ± s.e.mean . B) Histograms of C38:4 PI(3,4,5)P3 levels in WT and KO platelets stimulated 
with CRP-XL (1µg/mL, 5 min) in the absence or presence of TPO (100 ng/mL). PI(3,4,5)P3 levels 
were determined using phosphate methylation in conjunction with HPLC/MS. Data are peak 
area measurements, n = 3 ± s.e.mean. C) Representative immunoblot examining activation of 
PI3K signalling induced by CRP-XL, TPO and CRP-XL+TPO. Histograms demonstrate that 
phosphorylation of Akt at Thr308 and GSK3/ at Ser21/9 was not significantly altered in KO 
platelets. In contrast phosphorylation of Akt at Ser473 was significantly enhanced in response 
to CRP-XL in KO platelets compared to WT. n = 4/5 ± s.e.mean. Statistical analysis was 
performed using a two-way ANOVA followed by Sidak’s multiple comparison post-hoc test. 
**; p < 0.01. 
 
Figure 4. Amplification of TPO-mediated priming of thrombus formation is driven by 
enhanced TxA2 production. A) Histogram of TxB2 in supernatants collected from platelets 
stimulated with CRP-XL (0.5 g/mL), TPO (100 ng/mL) and CRP-XL+TPO. TxB2 levels were 
quantified by ELISA (Enzo Life Sciences, Exeter, UK). The data demonstrate that TxA2 
production induced by CRP-XL+TPO is enhanced in KO platelets, n = 5 ± s.e.mean. B) 
Representative images of platelet deposition on collagen acquired from the collagen base (z-
position = 0 µm) at 4 µm increments to a max thrombus height of 12 µm as indicated. 
Fluorescently labelled anti-coagulated whole blood from WT and p110α KO mice, pre-treated 
with TPO (100 ng/mL, 5 min) in the absence (i) or presence (ii) of acetylsalicylic acid (ASA, 
aspirin; 30 M) was perfused at an arterial shear rate of 1000s-1 over collagen-coated (50 
µg/mL) Vena8 glass-bottomed biochips (Cellix Ltd Microfluidic Solutions, Ireland), before 
fixation with 4% PFA.  Images were acquired using a Leica SP5-II confocal LSM. C) Analysis of 
total thrombus volume performed using Image J 1.46 (NIH, USA) and Volocity 6.1.1 (Perkin 
Elmer Inc, USA) revealed that ASA ablated TPO’s ability to amplify thrombus formation. Data 
represent the average results taken from 5 random microscopic fields per experimental 
condition, n = 6 ± s.e.mean. Statistical analysis was performed using a two-way ANOVA 
followed by Sidak’s multiple comparison post-hoc test. **; p < 0.01. 
 
Figure 5. MEK/ERK pathway is implicated in driving enhanced TxA2 production in p110 KO 
platelets. A) Histogram of TxB2 concentration in supernatants collected from platelets pre-
treated with 0.2% DMSO, PD184352 (300 nM), VX-702 (300 nM), PIK-75 (50 nM) or TGX221 
(200 nM) for 15 min before stimulation with CRP-XL (0.5 g/mL, 5 min) in the absence or 
presence of TPO (100 ng/mL, 5 min pre-treatment). TxB2 levels were quantified by ELISA (Enzo 
Life Sciences, Exeter, UK). The data demonstrate that TxA2 production induced by CRP-XL+TPO 
was enhanced in KO platelets and that this enhancement was reduced in the presence of 
PD184352. TGX221 was found to ablate TxA2 generation induced by CRP-XL alone and the 
combined treatment. n = 4 ± s.e.mean. B) Representative immunoblot examining the 
activation of MAPK and PKC pathways in WT and p110 KO platelets. Histogram 
demonstrates that CRP-XL and CRP-XL+TPO-mediated phosphorylation of ERK1/2 at 
Thr202/Tyr204 was significantly enhanced in KO platelets, n = 7 ± s.e.mean. In contrast 
phosphorylation of p38 at Thr180/Tyr182 and of the PKC substrate; pleckstrin was unaltered 
in KO platelets, n = 4 ± s.e.mean. Statistical analysis was performed using a two-way ANOVA 
followed by Sidak’s multiple comparison post-hoc test. **; p < 0.01, ***; p < 0.001.   
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Supplementary Figure 1. A) Pre-treatment of platelets with TPO at indicated concentrations 
can enhance CRP-XL mediated TxB2 generation, furthermore these increases in TxB2 
generation are greater in p110 deficient (KO) platelets compared to WT control. n = 3 ± 
s.e.mean. B) Histogram of TxB2 concentration in supernatants collected from platelets pre-
treated with 0.2% DMSO or the p110 inhibitor; A66 (300 nM) for 15 min before stimulation 
with CRP-XL in the absence or presence of TPO. n = 5 ± s.e.mean. TxB2 levels were quantified 
by ELISA (Enzo Life Sciences, Exeter, UK). Statistical analysis was performed using a two-way 
ANOVA followed by Sidak’s multiple comparison post-hoc test. *; p<0.05, **; p< 0.01, ***; p< 
0.001.   
 
